For the first time in the history of federal drug law, marijuana products operating under state medical programs have been moved out of Schedule I. On April 23, 2026, Acting Attorney General Todd Blanche signed a final order transferring FDA-approved marijuana products and all cannabis subject to a state medical marijuana license from Schedule I to Schedule III of the Controlled Substances Act - effective immediately. The order does not touch recreational cannabis, but its consequences for patients, operators, lenders, and researchers are immediate and substantial.
What Schedule III Actually Changes
Schedule I has long functioned as a kind of federal wall: substances classified there are deemed to have no accepted medical use and a high potential for abuse, which has made it legally treacherous - and in many cases functionally impossible - for state-licensed cannabis businesses to operate in any meaningful compliance with federal law. Schedule III carries none of those prohibitions. It includes substances with accepted medical use and a moderate to low potential for dependence. Anabolic steroids and ketamine sit there. Now, state-licensed medical marijuana does too.
The practical shift this creates is not abstract. Under the Internal Revenue Code, Section 280E bars businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses - rent, payroll, marketing, equipment. For state-licensed cannabis operators, 280E has functioned as a punishing tax surcharge, often pushing effective federal tax rates well above what comparable businesses in any other sector pay. With medical marijuana now in Schedule III, 280E no longer applies to state-licensed operators. The final order sets the effective date for that relief at January 1, 2026, and the U.S. Department of the Treasury has announced it will issue additional guidance on implementation - including the possibility of retroactive relief. That is not a trivial detail. Operators who have been absorbing 280E burdens for years may have legal arguments for recoupment.
Here's the catch, though: none of this applies automatically to adult-use operators. Businesses running recreational programs remain in Schedule I's shadow, and dual-license operators - companies holding both medical and adult-use licenses - face genuine uncertainty about whether DEA will require structural separation before granting or maintaining registration.
DEA Registration: A New Federal Pathway, With a Hard Deadline
The order creates an expedited DEA registration process for state-licensed medical marijuana companies. Once registered, those entities may manufacture, distribute, dispense, import, and export marijuana under federal law. That is a sentence worth pausing on. Interstate and even international commercial activity - effectively unthinkable under Schedule I - now exists as a legal possibility, however uncharted the practical road may be.
The window matters. Operators who apply for DEA registration within 60 days of the order's publication may continue operating under their state licenses while DEA reviews their applications. DEA must process those early applications within six months. Miss the 60-day window, and that protection disappears. The timeline is not a formality - it is a structural incentive built into the order to push operators toward federal compliance quickly, and companies that sit on their hands risk forfeiting meaningful procedural protections.
Import and export remain genuinely open questions. DEA has historically maintained tight control over marijuana exports even when legal authority existed on paper. Whether the agency's enforcement posture shifts alongside the regulatory text is something the industry will have to watch closely.
The Rulemaking That Isn't Over
The final order does not end the broader rescheduling proceeding that was initiated under the previous administration. That formal rulemaking continues - now focused exclusively on marijuana not covered by a state medical license, meaning recreational and unregulated cannabis. The DEA has cancelled the long-delayed Administrative Law Judge hearing associated with the prior proceeding and announced a new hearing beginning June 29, 2026, concluding no later than July 15. Interested parties have 30 days from publication of the scheduling order to request participation.
To put it plainly: the fight over where recreational cannabis lands in federal law is still very much live. The industry would benefit from presenting a unified position that adult-use cannabis belongs in Schedule III alongside medical marijuana. That alignment is easier to call for than to achieve - factions within and outside the industry have competing interests - but the administrative record being built in this rulemaking will carry legal weight for years.
Litigation is also coming. The CSA allows parties aggrieved by a scheduling order to petition directly for judicial review in federal appellate court, and legal challenges to the April 23 order are expected promptly. Challengers are likely to seek a stay. The order includes a severability provision, which means even a successful challenge to one component would not necessarily unravel the entire framework. Still, operators building business strategy around this order should account for the possibility of prolonged federal court proceedings.
Research, Capital, and What Comes Next
One underappreciated provision of the order: researchers may now obtain marijuana and marijuana-derived products directly from state licensees for scientific study, provided both parties are DEA registered. This matters more than it might appear. Federal research on cannabis has long been constrained to government-supplied material that often bears little resemblance to what patients actually use in state-regulated programs. The gap between research inputs and real-world products has been a persistent problem for clinical science. This provision doesn't close that gap entirely, but it opens a door that has been bolted shut for decades.
On the capital side, the downstream effects are still being priced in. Banking relationships for cannabis businesses have historically been constrained by federal illegality concerns. Rescheduling for the medical sector changes the federal compliance calculus for lenders and may draw new institutional capital into a sector that has operated largely on the margins of conventional finance. The major U.S. stock exchanges have not yet commented on whether rescheduling will affect listing eligibility for cannabis companies, but the question is now live in a way it wasn't before April 23. Intellectual property protection, bankruptcy access for medical operators, and interstate commerce - each of these areas carries real legal complexity that the order opens without fully resolving.
What this moment represents, stripped of hyperbole, is a structural inflection point. Decades of federal prohibition created a legal environment where state-licensed cannabis businesses operated in a kind of permanent legal ambiguity - compliant with state law, in technical violation of federal law, and unable to fully access the financial and regulatory systems available to every other lawful industry. For the medical sector, that ambiguity has now materially narrowed. The road ahead still has obstacles - litigation, rulemaking, open questions about dual-license operators, and the unresolved status of adult use. But the federal posture toward state-licensed medical marijuana has shifted in a way that cannot be undone simply by administrative inaction.
